Analyst Price Targets — RMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 13, 2026 2:44 pm | Anthony Petrone | Evercore ISI | $255.00 | $228.33 | TheFly | ResMed price target lowered to $255 from $300 at Evercore ISI |
| January 30, 2026 12:54 pm | Craig Wong-Pan | RBC Capital | $314.00 | $254.08 | TheFly | ResMed price target raised to $314 from $311 at RBC Capital |
| January 30, 2026 12:40 pm | — | Stifel Nicolaus | $265.00 | $257.61 | TheFly | ResMed price target raised to $265 from $260 at Stifel |
| January 30, 2026 12:40 pm | Brett Fishbin | KeyBanc | $302.00 | $257.61 | TheFly | ResMed price target raised to $302 from $299 at KeyBanc |
| January 30, 2026 12:25 pm | — | Robert W. Baird | $281.00 | $257.61 | TheFly | ResMed price target raised to $281 from $275 at Baird |
| January 30, 2026 12:04 pm | — | Piper Sandler | $275.00 | $257.61 | TheFly | ResMed price target raised to $275 from $270 at Piper Sandler |
| December 18, 2025 9:02 am | Jonathan Block | Stifel Nicolaus | $260.00 | $245.94 | StreetInsider | ResMed (RMD) PT Lowered to $260 at Stifel |
| December 16, 2025 10:19 am | — | Robert W. Baird | $275.00 | $253.07 | TheFly | ResMed downgraded to Neutral from Outperform at Baird |
| December 12, 2025 2:38 pm | Marcus Curley | UBS | $345.00 | $251.38 | StreetInsider | ResMed (RMD) PT Raised to $345 at UBS |
| November 3, 2025 12:08 pm | — | Robert W. Baird | $300.00 | $246.88 | TheFly | ResMed price target lowered to $300 from $320 at Baird |
Latest News for RMD
Lbp Am Sa boosted its stake in shares of ResMed Inc. (NYSE: RMD) by 364.1% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,125 shares of the medical equipment provider's stock after acquiring an additional 18,142 shares during the quarter. Lbp
RMD's growth strategy, rising device demand and solid finances support momentum, but macro pressures and stiff competition could test its outlook.
ResMed Inc. (NYSE: RMD - Get Free Report) CEO Michael Farrell sold 4,991 shares of the stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $225.50, for a total transaction of $1,125,470.50. Following the completion of the transaction, the chief executive officer owned 466,223 shares in
Aaron Wealth Advisors LLC lessened its stake in shares of ResMed Inc. (NYSE: RMD) by 53.3% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,938 shares of the medical equipment provider's stock after selling 2,210 shares during the period. Aaron Wealth
Azzad Asset Management Inc. ADV lifted its position in shares of ResMed Inc. (NYSE: RMD) by 271.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,463 shares of the medical equipment provider's stock after buying an additional 3,261 shares during the quarter. Azzad Asset
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.